ArticleModern rheumatology2012
Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis.
Article in Modern rheumatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 74 citations in OpenAlex.
- Recommendations for the Management of Neuro-Behçet's Disease by the Japanese National Research Committee for Behçet's Disease.Internal medicine (Tokyo, Japan) · 2020Pooled it
- Distinct clinical features between acute and chronic progressive parenchymal neuro-Behçet disease: meta-analysis.Scientific reports · 2017Pooled it
- Trial
- Neuro-behcet's syndrome: epidemiology, mechanisms, and emerging strategies in diagnosis and treatment.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Review
- Acute neurological Behçet's disease complicated by a syndrome of inappropriate secretion of antidiuretic hormone.BMJ case reports · 2026Article
- CD39 in the pathogenesis of neuro-Behçet disease: is it an immune regulator marker?Frontiers in immunology · 2026Review
- Development of Severity Classification Criteria for Acute Neuro-Behçet's Disease.Internal medicine (Tokyo, Japan) · 2026Article
- Neuro-Behçet's disease: an update of clinical diagnosis, biomarkers, and immunopathogenesis.Clinical and experimental immunology · 2025Review
- Effect of Infliximab on Chronic Progressive Neuro-Behçet's Disease: Influence of the Timing of Introduction on the Patient Outcome.Internal medicine (Tokyo, Japan) · 2024Article
- Cerebrospinal Fluid Analysis in Rheumatological Diseases with Neuropsychiatric Complications and Manifestations: A Narrative Review.Diagnostics (Basel, Switzerland) · 2024Review
- Association of high disease activity and serum IL-6 levels with the incidence of inflammatory major organ events in Behçet disease: a prospective registry study.Frontiers in immunology · 2024Article
- Case report: Adult case of A20 haploinsufficiency suspected as neuro-Behçet disease.Frontiers in immunology · 2024Article
- Development of neuro-Behcet's disease in a patient with operable HER2-positive breast cancer during neoadjuvant chemotherapy: A case report.Breast disease · 2024Article
- Neuro-Behçet With a Thalamic Lesion: A Case Report.Cureus · 2023Article
- Innate immune responses in Behçet disease and relapsing polychondritis.Frontiers in medicine · 2023Review
- Increased T-bet/GATA-3 and ROR-γt /Foxp3 Ratios in Cerebrospinal Fluid as Potential Criteria for Definite Neuro-Behçet's Disease.Journal of clinical medicine · 2022Article
- Prognostic factors for relapse and poor outcome in neuro-Behçet's syndrome: results from a clinical long-term follow-up of a single centre.Journal of neurology · 2022Article
- Surgical Treatment for Mesial Temporal Lobe Epilepsy Accompanied with Neuro-Behçet's Disease: A Case Report.NMC case report journal · 2021Article
- Surprise of Behcet's disease in a patient with bilateral disc oedema and the role of OCT.BMJ case reports · 2020Article
- Behçet's Disease with Severe Autonomic Disorders Developing after Herpes Zoster.Internal medicine (Tokyo, Japan) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To delineate the clinical characteristics of neuro-Behçet's disease (NBD), a multicenter retrospective survey was performed in BD patients who had presented any neurological manifestations between 1988 and 2008. The diagnosis of acute NBD, chronic progressive (CP) NBD, and non-NBD was confirmed by retrospective review of clinical records. Data on a total of 144 patients were collected; 76 with acute NBD, 35 with CP NBD, and 33 with non-NBD. High-intensity lesions on T2-weighted magnetic resonance imaging (MRI) were found in 60.5% of the patients with acute NBD, 54.2% with CP NBD, and 42.4% with non-NBD, whereas brainstem atrophy was observed in 7.5% with acute NBD, 71.4% with CP NBD, and 9.0% with non-NBD. The cerebrospinal fluid (CSF) cell count was prominently elevated in patients with acute NBD, but was normal in about 15% of those with CP NBD. The sensitivity and specificity of the CSF cell count for the diagnosis of acute NBD versus non-NBD were 97.4 and 97.0%, respectively (cut-off 6.2/mm(3)). The sensitivity and specificity of CSF interleukin (IL)-6 for the diagnosis of CP NBD versus the recovery phase of acute NBD were 86.7 and 94.7%, respectively (cut-off 16.55 pg/ml). The results indicate that elevation of the CSF cell count and CSF IL-6 and the presence of brainstem atrophy on MRI are useful for the diagnosis of NBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.